Eight peptides. Tiered honestly.
Each entry classifies evidence per indication. The same peptide can be Tier 1 for one use and Tier 4 for another — the tier reflects what the published literature actually supports, independent of community framing.
- Tier 3
BPC-157
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing. Human evidence is essentially absent — community framing far outpaces the data.
- Half-life
- ~4 hours (animal data; human PK not characterized)
- Route
- Subcutaneous / Intramuscular / Oral (research only)
- Indications
- 4 indexed
- Tier 3
CJC-1295
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- Half-life
- CJC-1295 with DAC: ~5–8 days. No DAC (MOD-GRF 1-29): ~30 minutes.
- Route
- Subcutaneous
- Indications
- 3 indexed
- Tier 2
GHK-Cu
Copper tripeptide
Strong topical evidence in skin and wound healing. Injectable systemic claims are an entirely different evidence base and tier.
- Half-life
- Topical: localized retention. Systemic injected: not well characterized.
- Route
- Topical (creams/serums) / Subcutaneous (research only)
- Indications
- 3 indexed
- Tier 3
Ipamorelin
GHRP / ghrelin mimetic
Selective GH secretagogue with minimal cortisol or prolactin elevation in animal studies. Human evidence is limited.
- Half-life
- ~2 hours
- Route
- Subcutaneous / Intramuscular
- Indications
- 4 indexed
- Tier 1
Semaglutide
GLP-1 receptor agonist
The most-studied GLP-1 agonist in modern medicine, with Tier 1 evidence for diabetes, weight loss, and major adverse cardiovascular events.
- Half-life
- ~7 days (supports once-weekly dosing)
- Route
- Subcutaneous / Oral (Rybelsus formulation)
- Indications
- 4 indexed
- Tier 3
TB-500
Thymosin Beta-4 fragment
Animal-data peptide marketed as a tissue-repair adjunct. No published human RCTs for musculoskeletal indications.
- Half-life
- ~2–3 hours (animal data; human PK not characterized for the fragment)
- Route
- Subcutaneous / Intramuscular
- Indications
- 3 indexed
- Tier 1
Tesamorelin
GHRH analog
FDA-approved for HIV-associated lipodystrophy. Off-label use for general fat loss is meaningfully less supported.
- Half-life
- ~30 minutes (pulsatile GH effect persists hours longer)
- Route
- Subcutaneous
- Indications
- 5 indexed
- Tier 1
Tirzepatide
GLP-1 / GIP dual agonist
FDA-approved dual incretin agonist with the strongest weight-loss and glycemic data in this library.
- Half-life
- ~5 days (supports once-weekly dosing)
- Route
- Subcutaneous
- Indications
- 4 indexed